Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · IEX Real-Time Price · USD
26.09
+0.55 (2.15%)
At close: May 3, 2024, 4:00 PM
25.58
-0.51 (-1.95%)
After-hours: May 3, 2024, 5:31 PM EDT
Protagonist Therapeutics Employees
Protagonist Therapeutics had 112 employees on December 31, 2023. The number of employees increased by 7 or 6.67% compared to the previous year.
Employees
112
Change (1Y)
7
Growth (1Y)
6.67%
Revenue / Employee
$535,714
Profits / Employee
-$704,955
Market Cap
1.52B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 112 | 7 | 6.67% |
Dec 31, 2022 | 105 | -13 | -11.02% |
Dec 31, 2021 | 118 | 39 | 49.37% |
Dec 31, 2020 | 79 | 6 | 8.22% |
Dec 31, 2019 | 73 | 9 | 14.06% |
Dec 31, 2018 | 64 | 9 | 16.36% |
Dec 31, 2017 | 55 | 20 | 57.14% |
Dec 31, 2016 | 35 | 6 | 20.69% |
Dec 31, 2015 | 29 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
National HealthCare | 13,123 |
Warby Parker | 3,491 |
Veracyte | 815 |
LeMaitre Vascular | 630 |
InMode | 581 |
Dynavax Technologies | 408 |
Ardelyx | 267 |
Kura Oncology | 142 |
PTGX News
- 5 weeks ago - Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data - Accesswire
- 6 weeks ago - Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda - Accesswire
- 2 months ago - Protagonist Therapeutics to Participate in Upcoming Investor Conferences - Accesswire
- 2 months ago - Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Accesswire
- 2 months ago - New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera - Accesswire
- 2 months ago - Protagonist Therapeutics Reports Granting of Inducement Awards - Accesswire
- 3 months ago - New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study - Accesswire
- 3 months ago - Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset - Accesswire